Get the Daily Brief
Latest Biotech News
Novartis to sell India generics unit—PE takeover for $159M
Novartis announced plans to transfer its 70.68% holding in Novartis India Limited to a private‑equity consortium in a deal valued at about $159 million, while retaining separate commercial and R&D...
Ionis halts Alzheimer’s program for people with Down syndrome
Ionis Pharmaceuticals confirmed it has stopped development of an investigational Alzheimer’s candidate intended for people with Down syndrome. The company said the decision followed an internal...
Korsana emerges with $175M to back Alzheimer’s shuttle antibody program
Korsana Biosciences surfaced from stealth with $175 million in financing to develop KRSA‑028, a blood‑brain‑barrier shuttle monoclonal antibody targeting amyloid‑beta. The Boston‑based startup...
Element launches Vitari—aims $100 30X genome with high‑throughput platform
Element Biosciences announced Vitari, a new high‑throughput sequencing platform that the company says can produce roughly 3 terabytes per run and sequence a 30X human genome for $100 in 36 hours....
Insilico and Lilly outline 'prompt‑to‑drug' vision—AI‑first R&D framework revealed
Researchers from Insilico Medicine and Eli Lilly published a framework in ACS Central Science describing a pathway toward fully autonomous, AI‑driven 'prompt‑to‑drug' discovery — integrating...
Grail’s Galleri test flops -- shares halve after UK trial misses endpoint
Grail reported that its large NHS-backed trial of the Galleri multicancer early detection (MCED) blood test failed to meet the study’s primary endpoint of a statistically significant reduction in...
FDA formalizes one‑trial default: regulators shift approval bar
Top FDA officials published a New England Journal of Medicine perspective making a single well‑controlled pivotal trial the agency’s new “default” standard for drug approvals, while asking...
Japan backs first iPSC drugs: conditional approvals advance regenerative therapies
Japan’s regulatory advisory panel recommended conditional approvals for two induced pluripotent stem cell (iPSC) therapies—Amchepry (raguneprocel) and Reheart—under the country’s conditional early...
Guardant doubles down on screening -- buys MetaSight and lifts 2026 guidance
Guardant Health disclosed strategic expansion of its cancer‑screening business, acquiring MCED startup MetaSight Diagnostics for $59 million upfront plus contingent payments and forecasting...
Novartis to divest India branded generics arm — keeps R&D and commercial footprint
Novartis confirmed plans to sell its 70.68% stake in Novartis India Limited to a private‑equity consortium for about $159 million while retaining separate commercial and R&D operations in the...
Korsana raises $175M to chase Alzheimer’s brain‑shuttle antibodies
Korsana Biosciences emerged from stealth with $175 million to advance KRSA‑028 and other CNS antibody programs designed to penetrate the blood‑brain barrier using a shuttle strategy. The...
Pepyrus improves HLA peptide detection with custom peptide libraries
Researchers unveiled Pepyrus, a platform that uses user‑defined peptide libraries produced in Escherichia coli to enhance mass‑spectrometry detection of HLA‑bound tumor peptides, improving...
AI ‘prompt‑to‑drug’ and lab‑in‑loop evolution push autonomous discovery
Researchers from Insilico Medicine and Eli Lilly published a vision for a fully autonomous “prompt‑to‑drug” R&D pipeline that stitches together generative AI, automated synthesis and iterative...
Plasma p‑tau217 ‘clocks’ estimate timing of Alzheimer’s symptom onset
Researchers developed plasma p‑tau217‑based clock models that predict the age of symptomatic Alzheimer’s onset within a three‑ to four‑year margin of error by correlating blood p‑tau217 dynamics...
Alpibectir combination shows proof‑of‑concept against drug‑resistant TB
Bioversys reported first clinical proof‑of‑concept data for alpibectir (BVL‑GSK098) combined with ethionamide in pulmonary tuberculosis, publishing phase IIa early bactericidal activity results in...
Insilico and Lilly Outline 'Prompt‑to‑Drug' Vision: Autonomous AI for drug discovery
Researchers from Insilico Medicine and Eli Lilly published a framework in ACS Central Science proposing a fully autonomous “prompt‑to‑drug” pipeline that links generative AI, automated synthesis,...
Element Debuts Vitari: $100 30X Genome, High‑Throughput Sequencing Push
Element Biosciences unveiled Vitari, a high‑throughput sequencing platform the company says can generate 3 terabytes per paired‑end 150 bp run in 36 hours and sequence a 30X human genome for $100....
Guardant Eyes Screening Ramp, Buys MetaSight to Expand MCED Portfolio
Guardant Health guided to substantial screening growth in 2026 for its Shield colorectal cancer screening test and disclosed an acquisition of early cancer detection startup MetaSight Diagnostics....
Grail's Galleri Fails Primary Goal in NHS Trial — Stock Collapses
Grail reported that its large UK NHS‑Galleri multicancer early detection (MCED) trial did not meet the primary endpoint of a statistically significant reduction in Stage III–IV cancers. The...
FDA Reverses Refusal, Will Review Moderna's mRNA Flu Shot
After initially issuing a Refusal to File over comparator and study‑design concerns, the FDA reversed course and agreed to review Moderna’s seasonal influenza BLA for mRNA‑1010. Moderna said it...